Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics

NCT01210755 ·Status: COMPLETED ·Phase: PHASE4

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects

NCT05491460 ·Status: UNKNOWN ·Phase: PHASE1

Direct Oral Anticoagulants and Venous Thromboembolism

NCT02833987 ·Status: COMPLETED

Thrombosis and Haemorrhage in Chronic Hemodialysis Patients

NCT02897258 ·Status: COMPLETED

Predictive Factors for Response to New Oral Anticoagulants in the Treatment of Non-valvular Atrial Fibrillation..

NCT04297150 ·Status: UNKNOWN

The Prevalence of Sub Optimal Anti Coagulation

NCT03485300 ·Status: UNKNOWN

Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants

NCT02720328 ·Status: COMPLETED ·Phase: PHASE4

Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography

NCT02448901 ·Status: UNKNOWN

Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism

NCT02977013 ·Status: COMPLETED

Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism

NCT02898051 ·Status: UNKNOWN

Factors Associated to the Instability of the INR (International Normalized Ratio ) in the Prevention of Thromboembolism AVK (Anti Vitamin K) in Atrial Fibrillation in the Elderly: Instead of Comorbidities

NCT02841475 ·Status: COMPLETED

Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study

NCT01704053 ·Status: COMPLETED

Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation

NCT03280368 ·Status: COMPLETED

Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)

NCT02906527 ·Status: UNKNOWN

Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation

NCT02666157 ·Status: UNKNOWN ·Phase: PHASE4

Specific Anti Factor Xa Activity Dosage to Enhance Detection of Nonadherence in Atrial Fibrillation Patients

NCT02925247 ·Status: COMPLETED ·Phase: NA

Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France

NCT02864758 ·Status: COMPLETED

Evaluation of the Impact of an Expert Opinion During the Management of Patients With Severe Bleeding on Oral Anticoagulants.

NCT05928091 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Register for New Oral Anticoagulants

NCT01588119 ·Status: UNKNOWN

An Open-label Study of KW-3357

NCT01384903 ·Status: COMPLETED ·Phase: PHASE3

Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions

NCT02898090 ·Status: COMPLETED

DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic

NCT03112525 ·Status: COMPLETED

Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure

NCT03568890 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients

NCT02792335 ·Status: COMPLETED

A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban

NCT02207725 ·Status: COMPLETED ·Phase: PHASE3